Genetic Aberrations and Interaction of NEK2 and TP53 Accelerate Aggressiveness of Multiple Myeloma

Xiangling Feng, Jiaojiao Guo, Gang An, Yangbowen Wu, Zhenhao Liu, Bin Meng, Nihan He, Xinying Zhao, Shilian Chen, Yinghong Zhu, Jiliang Xia, Xin Li, Zhiyong Yu, Ruixuan Li, Guofeng Ren, Jihua Chen, Minghua Wu, Yanjuan He, Lugui Qiu, Jiaxi Zhou, and Wen Zhou*

It has been previously shown that (never in mitosis gene A)-related kinase 2 (NEK2) is upregulated in multiple myeloma (MM) and contributes to drug resistance. However, the mechanisms behind this upregulation remain poorly understood. In this study, it is found that amplification of NEK2 and hypermethylation of distal CpG islands in its promoter correlate strongly with increased NEK2 expression. Patients with NEK2 amplification have a poor rate of survival and often exhibit TP53 deletion, which is an independent prognostic factor in MM. This combination of TP53 knockout and NEK2 overexpression induces asymmetric mitosis, proliferation, drug resistance, and tumorigenic behaviors in MM in vitro and in vivo. In contrast, delivery of wild type p53 and suppression of NEK2 in TP53−/− MM cell lines inhibit tumor formation and enhance the effect of Bortezomib against MM. It is also discovered that inactivating p53 elevates NEK2 expression genetically by inducing NEK2 amplification, transcriptionally by increased activity of cell cycle-related genes like E2F8 and epigenetically by upregulating DNA methyltransferases. Dual defects of TP53 and NEK2 may define patients with the poorest outcomes in MM with p53 inactivation, and NEK2 may serve as a novel therapeutic target in aggressive MM with p53 abnormalities.

1. Introduction

Multiple myeloma (MM) is a cancer of terminally differentiated plasma cells and is the second most common hematological malignancy.[1] The pathogenesis of MM involves several genetic alterations.[2] These changes include primary cytogenetic abnormalities (e.g., translocations involving chromosome 14q and trisomies of odd-numbered chromosomes) and secondary lesions (e.g., gain of chromosome 1q and loss of chromosome 17p).[3]

Cancer-related genes are broadly grouped into oncogenes and tumor suppressor genes. The abnormal activation of oncogenes such as CCND1, CCND2, CCND3, and FGFR3 has been reported in MM.[2,4] DNA gains and losses that result in copy number alterations cause oncogene activation and tumor suppressor gene inactivation; these are the driving events leading to the development and progression...
of MM.\(^1,2,5\) For example, the amplification of chromosome 1q, which harbors a number of potentially relevant oncogenes such as C\textsc{k}s1\textsc{b},\(^6\) IL\textsc{f}2,\(^7\) AN\textsc{p}3\textsc{Z}2E,\(^8\) and P\textsc{d}ZK\textsc{1},\(^9\) contributes to MM cell proliferation. Deletion of 17\(p\), where TP53 is located, also plays an important role in MM progression.\(^10\) However, how these oncogenes collaborate with tumor suppressor genes to accelerate MM initiation and progression is still poorly understood.

We have previously shown that increased chromosomal instability (CIN) signature is linked to drug resistance (DR) in MM.\(^11\) (Never in mitosis gene A)-related kinase 2 (NEK2), a CIN gene located at 1q32.2, is the most significant. NEK2 is a serine/threonine kinase\(^13\) that induces tumor cell proliferation, metastasis and drug resistance through regulation of several oncogenes or cell cycle-related molecules including \(\alpha\), \(\beta\) catenin and enhancer of zeste homolog 2 (EZH2)\(^15\) in MM and other types of cancer.\(^11,34\) It is associated with poor outcomes and drug resistance due to activating efflux drug pumps,\(^11\) autophagy,\(^14\) and ALDH1A1 in MM.\(^12\) Although several critical substrates and molecules downstream of NEK2 are involved in tumorigenesis, the mechanisms by which NEK2 is activated and cooperates with other molecules—especially key tumor suppressor genes like TP53—in MM cells are largely unknown.

Since 1q amplification and 17p deletion are both markers of the poorest prognosis in MM patients, we hypothesize that activated NEK2 and inactive p53 may have synergistic effects in MM progression. In this study, we determine the correlation of genetic aberrations and the functional relationship between TP53 and NEK2 in MM in vitro and in vivo.

2. Results

2.1. NEK2 Amplification and Promoter Hypermethylation Correlate with its Upregulation and are Associated with Poor Prognosis in MM

Genetic lesions (including translocation, amplification and mutations) and epigenetic changes (e.g., DNA methylation, microRNA regulation, and transcriptional regulation) cause aberrant gene expression.\(^17\) To investigate the mechanisms underlying aberrant expression of NEK2 in MM, we first analyzed DNA copy number variations (CNVs) and exome-sequencing and RNA-sequencing of 575 primary MM samples from the Multiple Myeloma Research Foundation (MMRF) CoMMpass database. We found that 24.2\% (139/575) of the patients showed NEK2 amplification (Amp) (Figure 1A), which correlated strongly with elevated NEK2 expression (Figure 1B). Moreover, a Kaplan-Meier survival analysis of the CNVs database containing 573 MM patients revealed that patients with NEK2 amplification had a significantly shorter overall survival (OS) (NEK2\(^\text{Amp}\) group, median, 40 months) than the patients with a normal copy number (NEK2\(^\text{N}\) group, median, 60 months, Figure 1C). Subsequent fluorescence in-situ hybridization (FISH) experiments using a probe for NEK2 and chromosome 1 control (CEP1) further confirmed these findings (Figure 1D). Compared with healthy donors (HD), NEK2 amplification (defined as \(\geq 20\%\) of CD138\(^+\) cells with three or more FISH signals) was detected in 23.5\% (5/17), 75\% (3/4), and 87.5\% (7/8) of newly diagnosed MM patients (AD), relapsed diagnosed MM patients (RD) and MM cell lines, respectively (Figure 1D and Table S1, Supporting Information), suggesting a link between NEK2 amplification and poor prognosis in MM.

Next, to determine the status of NEK2 mutations in MM cell lines, we analyzed all NEK2 exons and its promoter region from \(-1018\) to +1 bp in eight MM cell lines. One point mutation (A\(\rightarrow\)G, N354S) of seven exons was found only in the U266 cell line (Figure S1A.B, Table S2, Supporting Information), suggesting that the mutation may not be responsible for upregulation of NEK2 mRNA. Furthermore, two CpG islands in the regions from \(-700\) to \(-500\) bp (distal) and \(-200\) to +1 bp (proximal) were observed in the NEK2 promoter region (Figure S1B, Supporting Information). Methylation-specific PCR (MSP) revealed unmethylation of the proximal CpG island and partial methylation of the distal CpG island in seven MM cell lines and three MM patients (Figure 1E,F). The sequencing of MSP products further showed that all the cytosine residues were converted to thymine except for those in methylated CpG dinucleotides, indicating the presence of methylated cytosines in these CpG dinucleotides (Figure S1C, Supporting Information). These results suggest that amplification and distal methylation of NEK2 might be associated with its aberrant overexpression in MM.

2.2. NEK2 Amplification Correlates with Deletion/Mutation of TP53 in MM

It was previously shown that loss of TP53 is an independent prognostic factor in MM\(^10\) and that p53 can bind to the promoter of NEK2.\(^18\) These findings led us to assess the potential association between TP53 and NEK2 by using the CNVs database, containing 548 MM patients (excluding 25 MM patients with TP53 amplification and two patients with NEK2 deletion), from the MMRF CoMMpass database. First, we divided the samples into quartiles based on their expression levels of TP53 (high = TP53\(^\text{H}\), low = TP53\(^\text{L}\)) and NEK2 (high = NEK2\(^\text{H}\), low = NEK2\(^\text{N}\)). TP53 deletion (TP53\(^\text{Del}\)) was observed in 9.3\% (51/548) of MM samples and contributed to aberrantly high expression of NEK2 (Figure 2A). Among the TP53\(^\text{Del}\) MM patients, the frequency of NEK2 amplification (NEK2\(^\text{Amp}\)) was \(~25.5\%\) (13/51) and was also linked to high expression of NEK2 (Figure S2A, Supporting Information). In addition, the proportion of patients with NEK2 amplification increased in patients with TP53 deletion (Figure S2B, Supporting Information). The analysis of the CNVs database further showed that patients with concomitant TP53 deletion and NEK2 amplification (TP53\(^\text{Del}\&\text{NEK2}\) A\(mp\)) had a significantly shorter OS (median, 32.4 months) than those in the TP53\(^\text{Del}\) (44.8 months) and no TP53\(^\text{Del}\) and NEK2\(^\text{Amp}\) (TP53\(^\text{Del}\&\text{NEK2}\) L\(\text{low}\)) groups (not reached) (Figure 2B). Similarly, patients with concomitant TP53\(^\text{Del}\) and NEK2\(^\text{H}\) had a significantly shorter OS (median, 25.4 months) than others (TP53\(^\text{H}\) & NEK2\(^\text{N}\) and TP53\(^\text{L}\) & NEK2\(^\text{N}\), not reached; TP53\(^\text{H}\) & NEK2\(^\text{H}\), 55.7 months; Figure S2C, Supporting Information). We also found that mutation of TP53 (TP53\(^\text{Mut}\)) was observed in 5.4\% (40/743) of MM samples and was associated with aberrantly high expression of NEK2 (Figure 2C) using the MMRF CoMMpass database of 743 cases. The results further showed that patients with both TP53\(^\text{Mut}\) and NEK2\(^\text{H}\) had a significantly shorter OS (median, 25 months) than those without the two defects simul-
Figure 1. NEK2 amplification in MM patients is associated with poor outcomes. A) Assessment of NEK2 CNV distribution in MM patients (n = 575). B) The correlation between CNV and NEK2 mRNA expression, and data presented as mean ± SD, n = 573, p-values are calculated using unpaired t test, ****p < 0.0001. C) Kaplan-Meier analysis of overall survival in MM patients with or without NEK2 CNV amplification (n = 574). D) Left: Representative images of FISH analysis using probes specific for CEP1 (Green) and NEK2 (Red) in eight MM cell lines, healthy donors (HD, n = 4), and newly-diagnosed (AD, n = 17) and relapsed (RD, n = 4) MM patients. Upper: normal diploid. Middle: three copies. Lower: four copies (NEK2 amplification). Right: scatter plot showing statistical results of the proportion of cells with different NEK2 copy numbers in MM patients and MM cell lines. Data presented as mean ± SD, p-values are calculated using unpaired t test, *p < 0.05, **p < 0.01, ***p < 0.001. The MSP results of NEK2 proximal and distal CpG islands in E) seven MM cell lines and F) three MM patients. M, MSP products using methylation-specific primers; U, MSP products using methylation-unspecific primers.

Simultaneously (TP53N & NEK2L and TP53Mut & NEK2L, not reached; TP53N & NEK2H, 54.8 months; Figure 2D, Supporting Information).

To further examine the relationship between NEK2 and TP53 in other cancer types, we analyzed the copy number and mRNA levels of NEK2 in 24 different cancer types with TP53 abnormalities based on The Cancer Genome Atlas (TCGA) database. The cancer types included adrenocortical carcinoma, bladder urothelial cancer, breast invasive cancer, esophageal carcinoma, glioblastoma multiforme, kidney renal papillary cell carcinoma, liver hepatocellular carcinoma (LIHC), lung adenocarcinoma (LUAD), pancreatic adenocarcinoma, sarcoma, skin cutaneous melanoma, and stomach adenocarcinoma. We found that NEK2 expression was significantly upregulated in TP53Del or TP53Mut cancer samples compared to samples with normal TP53 genetic status (Figure S2D, Supporting Information). The copy number of NEK2 was also amplified and NEK2 mRNA levels were increased in TP53Del samples from these cancer types, except for LIHC and LUAD (Figure S2E, Supporting Information). These results implied that TP53 deletion or mutation (TP53Del/Mut) correlates with NEK2 amplification and elevates NEK2 expression in MM and other cancer types.

To assess the effect of NEK2 and TP53 expression and their roles in prognosis, we applied the Gene Expression Programing (GEP) database of 559 MM samples (GSE2658[5]). As shown in Figure 2E, TP53 expression (low in MM) correlated inversely with NEK2 expression in MM patients. Additionally, the MM patients with TP53N and concomitant NEK2L expression had a significantly inferior OS (median, 40.8 months), while patients with either NEK2L or TP53H had better outcomes (TP53H & NEK2L and TP53L & NEK2H, not reached; TP53H & NEK2H, 49 months; Figure 2F).

To further confirm whether NEK2 was amplified in TP53Del patients, we performed FISH using probes targeting the TP53 and NEK2 gene loci in MM clinical samples. The results showed ≥20% of CD138+ cells with three or more signals marked as NEK2 loci in 100% (4/4) of TP53Del MM samples (P31-34, Table S1, Supporting Information), and not in seven TP53Mut samples (P25-30, Table S1, Supporting Information) (Figure 2G). We also found that the number of cells containing three copies of
Figure 2. NEK2 expression is elevated in MM patients with TP53 lesions. A) NEK2 mRNA levels in MM patients with (n = 51) or without (n = 497) TP53 deletion, and data presented as mean ± SD, p-values are calculated using unpaired t test, ****p < 0.0001. B) Kaplan-Meier analyses of overall survival in MM patients with TP53\textsuperscript{N} & NEK2\textsuperscript{N} (normal), TP53\textsuperscript{D} & NEK2\textsuperscript{L} (deletion), TP53\textsuperscript{D} & NEK2\textsuperscript{H} (Amplification), and TP53\textsuperscript{D} & NEK2\textsuperscript{Amp} (n = 548). C) NEK2 mRNA levels in MM patients with (n = 40) or without (n = 703) TP53 mutation, and data presented as mean ± SD, p-values are calculated using unpaired t test, ****p < 0.0001. D) Kaplan-Meier analyses of overall survival in MM patients with wild type TP53 (TP53\textsuperscript{N}) & low expression NEK2 (NEK2\textsuperscript{L}), TP53\textsuperscript{N} & high expression NEK2 (NEK2\textsuperscript{H}), mutant TP53 (TP53\textsuperscript{mut}) & NEK2\textsuperscript{L} and TP53\textsuperscript{mut} & NEK2\textsuperscript{H} (n = 743). E) Correlation between NEK2 and TP53 mRNA expression in the TT2 and TT3 trial form GEP data (GSE2658, n = 559, p-values are calculated Pearson correlation coefficient ). F) Kaplan-Meier analyses of overall survival in TT2 and TT3 MM patients (n = 559) with high NEK2 (NEK2\textsuperscript{H}) & low TP53 expression (TP53\textsuperscript{L}), NEK2\textsuperscript{H} & high TP3 expression (TP53\textsuperscript{H}), low NEK2 (NEK2\textsuperscript{L}) & TP53\textsuperscript{H} and NEK2\textsuperscript{H} and TP53\textsuperscript{H}. G) Scatter plot showing the percentage of cells with amplified NEK2 copy number in MM patients with or without TP53 deletion. Data presented as mean ± SD, p-values are calculated using unpaired t test, ***p < 0.001, ****p < 0.0001. H) Scatter plot showing the percentage of cells with amplified NEK2 copy number in TP53\textsuperscript{W} or TP53\textsuperscript{−/−} MM cells. Data presented as mean ± SD, p-values are calculated using unpaired t test, *p < 0.05, **p < 0.01. I, J) Representative immunofluorescence images and statistical analysis for p53 (Green) and NEK2 (Red) protein expression in MM newly diagnosed patients (AD, n = 51) and relapsed patients (RD, n = 16, p-values are calculated using one-way ANOVA with Bonferroni correction).
Figure 3. NEK2 expression is reduced and correlates inversely with loss of wild type TP53 in MM cells. A) Relative mRNA levels of NEK2 and TP53 in the H929 TP53WT MM cell line were detected with qPCR after treatment with nutlin-3a for 48 h at concentrations of 0, 2, and 4 μM. Data presented as mean ± SD, p-values are calculated using unpaired t test, n = 3, **p < 0.01. B) Relative protein levels of p53, NEK2, and GAPDH in TP53WT H929 cells after treatment with 0, 2, and 4 μM of nutlin-3a for 48 h, as determined with immunoblotting. C) Relative mRNA levels of NEK2 and TP53 in the ARP1 TP53−/− MM cell line were detected with qPCR after treatment with nutlin-3a for 48 h at concentrations of 0, 2, and 4 μM. D) Relative protein levels of p53, NEK2, and GAPDH in TP53−/− ARP1 cells after treatment with 0, 2, and 4 μM of nutlin-3a for 48 h, as determined with immunoblotting. E) The mRNA levels of TP53 and NEK2 in H929 cells with or without TP53 deletion edited by CRISPR/Cas9, as determined with qPCR. Data presented as mean ± SD, p-values are calculated using unpaired t test, n = 3, **p < 0.001. F) p53 and NEK2 protein levels in H929 cells with or without CRISPR-Cas9-mediated TP53 deletion, as determined with immunoblotting. G) TP53 and NEK2 mRNA levels in MM.1s cells with or without CRISPR-Cas9-mediated TP53 deletion, as
NEK2 was significantly greater in TP53\textsuperscript{wt} MM cell lines (including ARP1 and KMS11) than in TP53\textsuperscript{wt} MM cell lines (including MM.1S and H929) (Figure 2H).

Finally, to verify whether the loss of p53 is linked to elevated NEK2 expression, we performed immunofluorescence (IF) to examine p53 and NEK2 protein levels in 51 newly diagnosed and 16 relapsed MM patients. As shown in Figure 2I, 9.8% (5/51) of newly diagnosed patients and 31.3% (5/16) of relapsed patients exhibited low p53 protein expression and high NEK2 protein expression, while in 66.7% (34/51) of new patients and 43.8% (7/16) of relapsed patients, the reverse was true. Experiments with Fisher’s exact probability test implied that p53 protein expression correlated inversely with NEK2 protein expression in MM. These results suggested that patients of the TP53\textsuperscript{wt}/MM MM subgroup are prone to NEK2 amplification and upregulation, leading to poor prognosis.

2.3. TP53 Deletion/Mutation Upregulates NEK2 in Myeloma Cells

To establish a causal relationship between TP53 deletion/mutation and NEK2 expression in MM, we induced p53 expression in H929 and ARP1 cell lines using different concentrations of nutlin-3a. A dose-dependent decrease of NEK2 mRNA and protein levels and a dose-dependent increase of TP53 and MDM2 mRNA and protein levels were observed in H929 cells (Figure 3A,B) but not in TP53\textsuperscript{−/−} ARP1 cells (Figure 3C,D).

We also assessed the effect of knocking out (KO) TP53 in HEK293 cells using the CRISPR-Cas9 gene editing technology. Cells infected with virus containing CRISPR-Cas9 or CRISPR-Cas9-TP53 vector were successfully established and were dubbed HEK293-Ctrl and HEK293-TP53\textsuperscript{KO}, respectively (Figure S3A–C, Supporting Information). TP53 deletion in HEK293 cells (HEK293-TP53\textsuperscript{KO}) caused NEK2 mRNA and protein levels to increase dramatically when compared with the control cells (Figure S3B,C, Supporting Information). Subsequently, p53 was successfully knocked out in H929 cells and knocked down in MM.1s cells established using the CRISPR-Cas9 system. These p53-deficient cell lines were named H929-TP53\textsuperscript{−/−} and MM.1s-TP53\textsuperscript{−/−}, respectively. We observed increased NEK2 mRNA and protein levels in both H929-TP53\textsuperscript{−/−} cells (Figure 3E,F) and MM.1s-TP53\textsuperscript{−/−} cells (Figure 3G,H).

We then obtained cell clones from H929-TP53\textsuperscript{KO} cells via sequential dilution and found that the NEK2 mRNA and protein levels were upregulated in clones with TP53 deletion (C1, C2, and C4) and more strongly in those with TP53 mutation (C3, C5) (Figure S3D,E, Supporting Information). The sequence forms of the DNA and protein from these clones were confirmed by sequencing (Figure S3F and Additional File S6, Supporting Information). Similar results were also seen in HCT116-TP53\textsuperscript{−/−} cells (Figure S3G,H, Supporting Information) and the Trp53\textsuperscript{tm1Tyj} TP53-knockout mouse genetic model (Figure S3I,J, Supporting Information).

In contrast, ectopic expression of WT TP53 in ARP1 cells caused NEK2 mRNA and protein levels to markedly decrease compared with empty vector (ARP1-EV), while ectopic expression of mutant TP53 with a hotspot mutation at E285K exerted no inhibitory effect (Figure 3J). Moreover, ectopic expression of mutant TP53 with hotspot mutations observed in MM and other tumors (Y126H, R175H, R228G, and E285K) in H929-TP53\textsuperscript{wt} and H929-TP53\textsuperscript{KO} cells caused slight elevation of NEK2 mRNA levels, while protein levels were increased dramatically (Figure 3K–N). These results indicate that TP53 deletion or mutation induces NEK2 upregulation.

2.4. NEK2 Activation and p53 Suppression Promote Mitotic Aberrations, Cell Proliferation, and Tumorigenesis in MM

To test the effect of dual defects of NEK2 and TP53 on MM, we overexpressed NEK2 in H929 cells (H929-NEK2 OE) and H929-TP53\textsuperscript{KO} cells (H929-TP53\textsuperscript{KO}/NEK2 OE), then performed functional assays in H929-Ctrl, H929-NEK2 OE, H929-TP53\textsuperscript{KO}, and H929-TP53\textsuperscript{KO}/NEK2 OE cells after determination of TP53 and NEK2 mRNA expression and protein levels (Figure S4A,B, Supporting Information).

We first examined the role of NEK2 in cell growth by using the clonogenic soft agar assay and BrdU intake assay, finding that H929-TP53\textsuperscript{KO}/NEK2 OE cells showed a significant elevation in colony formation (117 ± 7) compared with other groups including H929-NEK2 OE (68 ± 9), H929-TP53\textsuperscript{KO} (87 ± 5), and H929-Ctrl (28 ± 2, Figure 4A,B). The percentage of BrdU-positive cells in the H929-TP53\textsuperscript{KO}/NEK2 OE group (43.5 ± 0.4%) was much higher than that for other groups including H929-NEK2 OE (28.4 ± 2.0%), H929-TP53\textsuperscript{KO} (34.7%), and H929-Ctrl cells (14.3 ± 0.3%, Figure 4C,D). In addition, after NEK2 was depleted in H929-TP53\textsuperscript{KO}/shNEK2 cells via tetracycline-inducible shRNA-mediated knockdown, the number of colonies (57 ± 1, Figure 4A,B) and the percentage of BrdU-positive cells (16.8 ± 1.7%, Figure 4C,D) were drastically reduced compared to those of H929-TP53\textsuperscript{KO} cells.

Subsequently, we used an apoptosis assay to test the sensitivity of cells with combined NEK2/TP53 defects to Bortezomib (BTZ, a proteasome inhibitor and a first-line treatment in MM). We found that the percentage of apoptotic cells decreased significantly in the H929-TP53\textsuperscript{KO} group (75.7 ± 3.3%), and more prominently in the H929-TP53\textsuperscript{KO}/NEK2 OE group (67.2 ± 4.8%), after BTZ treatment (4 or 2 nM) when compared with the H929-Ctrl group (96 ± 1.8%) (Figure 4E,F, Figure S4C, D).
Figure 4. Dual defects in NEK2 and p53 enhance mitotic abnormalities, cell proliferation, apoptosis, and tumorigenesis in MM. A) Representative images of clonogenic analysis in H929-Ctrl, H929-TP53KO, H929-NEK2 OE, H929-TP53KO/NEK2 OE, and H929-TP53KO/shNEK2 cells (images are shown in 4x magnification). B) Statistical analysis of clone numbers formed in soft agarose of the five cell groups shown in panel (A). Data presented as mean ± SD, p-values are calculated using unpaired one-way ANOVA with Dunnett post-hoc test, n = 3, *p < 0.05, **p < 0.01, ***p < 0.001. C) Representative flow cytometry dot plots for detection of BrdU-positive cells among H929-Ctrl, H929-TP53KO, H929-NEK2 OE, H929-TP53KO/NEK2 OE, and H929-TP53KO/shNEK2 cells. D) Statistical analysis of the number of BrdU-positive cells among the five cell groups shown in panel (C). Data presented as
Supporting Information). In addition, after NEK2 was depleted in H929-TP53KO/shNEK2 cells, the percentage of apoptotic cells (91 ± 0.1%) was markedly increased compared with that in H929-TP53KO cells (Figure 4E,F, Figure S4C, Supporting Information).

Finally, we evaluated the effects of combined NEK2 and TP53 defects in vivo using MM xenograft models. We found that NEK2 overexpression and p53 knockdown separately could increase tumor growth, and this effect was significantly enhanced when the defects were combined in the H929-TP53KO/NEK2 OE group; meanwhile, tumor growth was decreased in the H929-TP53KO/shNEK2 group (Figure 4G,H, Figure S4D, Supporting Information). Immunohistochemistry (IHC) confirmed that the tumor cells from xenograft nodules were CD138+ plasma cells with NEK2 overexpression and p53 deletion (Figure S4E, Supporting Information). Also, the number of proliferative (Ki-67+) cells increased significantly in the H929-TP53KO/NEK2 OE group while decreasing in the H929-TP53KO/shNEK2 group (Figure 4I, Figure S4F, Supporting Information). Thus, dual defects in NEK2 and TP53 promote proliferation and tumorigenesis in MM.

2.5. TP53 Deletion Upregulates NEK2 via the Regulation of Chromosomal Instability-Related Genes

Because of the complexity of genetic abnormalities in cancer, we used HEK293 cells, with their relatively normal phenotype and genetic background, to examine whether p53 deletion or NEK2 overexpression can induce CIN. A comparative genomic hybridization (CGH) array was performed to scan the entire genome of normal HEK293 cells (HEK293-Ctrl), cells with NEK2 overexpression (HEK293-NEK2 OE) and HEK293-TP53KO cells. Notably, compared with HEK293-Ctrl, several high-risk genetic abnormalities, including deletion of chromosomes 5, 7q, 8, 9, and 17p and some gains of chromosomes 1, 2q, 3p, 4p, 6, 13q, and 14q, were observed in HEK293-TP53KO cells (Figure 5A, Table S3, Supporting Information). Fewer chromosomal changes were observed in HEK293-NEK2 OE cells compared with HEK293-Ctrl cells (Figure 5C, Table S4, Supporting Information). Interestingly, chromosome 1q21-44, where NEK2 is located, was dramatically amplified in HEK293-TP53KO cells (Figure 5B).

To verify the findings from the CGH array, we subsequently performed FISH in HEK293-Ctrl and HEK293-TP53KO cells using probes targeting the NEK2 and TP53 DNA regions. The number of cells with two copies of NEK2 decreased, while the number of cells with three or more copies increased significantly in the HEK293-TP53KO cells compared with the HEK293-Ctrl cells (Figure 5D). A similar pattern was observed for H929-TP53KO cells (Figure 5E). This evidence further suggests that p53 deletion is associated with NEK2 amplification in MM.

Interestingly, differentially expressed genes (Tables S5 and S6, Supporting Information) were mainly found in the cytoplasm and nucleus. They were mostly involved in spindle formation, chromosomal stability and gene transcription, as revealed by pathway enrichment analysis (Table S7 and S8, Supporting Information) when we used RNA-seq to examine the gene expression profiles in HEK293-Ctrl, HEK293-TP53KO, and HEK293-TP53KO/NEK2 OE cells. In addition, gene set enrichment analysis showed 1q32 amplification and major types of gene signatures enriched in CIN, cell proliferation, and p53 pathway (Figure 5F,G, Figure S5A, Supporting Information). The expression level of CIN-related genes was significantly altered in HEK293-TP53KO cells and more prominently in cells with combined defects in NEK2 and TP53 (Figure S5B, Supporting Information). We then verified the changes in the expression of CIN-related genes, including TP53, NEK2, BUBR1, HEC1, AURKA, AURKB, and MAD2L1, by using qPCR in HEK293 and H929 cells with or without TP53 deletion (Figure SSC,D, Supporting Information). Thus, p53 deletion leads to NEK2 amplification or overexpression, likely through the alteration of CIN-related genes.

Next, we used a spindle formation assay to demonstrate that the percentage of cells with abnormal mitosis (e.g., asymmetric spindle division, multipolar division, and nuclear condensation) increased significantly in the H929-NEK2 OE (22.4 ± 1.5%) and H929-TP53KO groups (21.5 ± 1.5%) when compared to the H929-Ctrl group (11.9 ± 0.3%), and an even greater increase was observed in the H929-TP53KO/NEK2 OE group (36.1 ± 1.2%, Figure 5H,I). We also depleted NEK2 in H929 cells with p53 deletion by using shRNA-mediated NEK2 knockdown (denoted as the H929-TP53KO/shNEK2 group), which rescued aberrant defects in spindle formation (14.3 ± 0.2%, Figure 5H,I).

2.6. TP53 Deletion Enhances NEK2 Expression Uregulation of E2F8

A non-canonical p53 recognition site (CCCATGTTG-GACGAGCCTGCTC), identical to the site from the huntingtin gene promoter, was previously identified at the distal promoter region of NEK2[18]. To test the function of this site, we constructed the full-length NEK2 promoter fragment (1098 bp from −1017 to −2 bp relative to the TSS, Figure S6A, Supporting Information) and a mutant NEK2 promoter with deletion of the p53 binding site and inserted them into the luciferase reporter vector PGL3-enhancer. We then co-transfected the fusion constructs together with the TP53 expression vector into HEK293-TP53KO and ARP1 cells. Luciferase activity in cells with mean ± SD, p-values are calculated using one-way ANOVA with Dunnett post-hoc test, n = 3, *p < 0.05, **p < 0.01, ***p < 0.001. E) Representative histograms for detection of apoptotic cells in H929-Ctrl, H929-TP53KO, H929-NEK2 OE, H929-TP53KO/NEK2 OE, and H929-TP53KO/shNEK2 cells treated with 4 nM BTZ for 48 h. F) Statistical analysis of the percentage of apoptotic cells among the five cell groups shown in panel (E) after treatment with 4 nM BTZ for 48 h. Data presented as mean ± SD, p-values are calculated using one-way ANOVA with Dunnett post-hoc test, n = 3, *p < 0.05, **p < 0.01, ***p < 0.001. G) Representative images of tumor xenografts from B-NDG mice with subcutaneous injections of H929-Ctrl, H929-TP53KO, H929-NEK2 OE, H929-TP53KO/NEK2 OE, or H929-TP53KO/shNEK2 cells into the right abdomen (6 mice measured for each group). H) Statistical analysis of tumor volumes of xenografts from B-NDG mice as shown in panel (G) (6 mice measured for each group). Data presented as mean ± SD, p-values are calculated using two-way ANOVA with Dunnett post-hoc test, n = 6, *p < 0.05, **p < 0.01, ***p < 0.001. I) Representative images for IHC detection of Ki-67 protein in the tumor nodules derived from B-NDG mice injected subcutaneously with H929-Ctrl, H929-TP53KO, H929-NEK2 OE, H929-TP53KO/NEK2 OE, or H929-TP53KO/shNEK2 cells.
Figure 5. TP53 deletion upregulates NEK2 expression by inducing amplification and chromosomal instability in MM cells. 

A) Comparative analysis of HEK293-TP53KO versus HEK293-Ctrl cells using CGH array. Red column represents gains of chromosomes. Blue column represents deletions. Chromosomal aberrations are across the whole genome. 

B) Schematic depiction of NEK2 location in chromosome 1q21.1-q44. 

C) Comparative analysis of HEK293-NEK2 OE versus HEK293-Ctrl cells using CGH array. Red column represents gain. Blue column represents deletion. 

D) Left, representative images of FISH analysis using probes targeting TP53 (17P, Red) and NEK2 (1q32.2, Green) in HEK293-Ctrl and HEK293-TP53KO cells. Right, scatter plot showing the percentage of cells from both groups with amplified NEK2 copy numbers. Data presented as mean ± SD, p-values are calculated using

---

Adv. Sci. 2022, 9, 2104491 © 2022 The Authors. Advanced Science published by Wiley-VCH GmbH
the full-length NEK2 promoter sequence decreased dramatically upon p53 expression, while it was mostly unaffected in cells containing the mutant promoter with p53 binding site deletion (Figure 6A,B, Figure S6B,C, Supporting Information). ChiP-qPCR analysis with an anti-p53 antibody showed enrichment of the p53 binding site in both the wild type (WT) and mutant (KO) promoters in H929-Ctrl and H929-TP53KO cells (Figure S6D, Supporting Information). This indicates that p53 suppresses NEK2 transcription by directly binding to the NEK2 promoter.

Subsequently, we analyzed the differentially expressed genes (Table S9, Supporting Information) obtained from gene expression profiles in H929-Ctrl, H929-TP53KO, and H929-TP53KO/NEK2 OE cells. CIN-related genes, along with genes in the cyclin and E2F families, were differentially expressed in H929-TP53KO cells and, to an even larger degree, in H929-TP53KO/NEK2 OE cells (Figure S6D, Supporting Information). These alterations of the E2F family expression profiles in H929-TP53KO cells and, to an even larger degree, in H929-TP53KO/NEK2 OE cells compared with the expression of the other two DNA methyltransferase genes (DNMT1 and DNMT3a) in H929-TP53KO cells (Figure 7E,F,G). aberrantly high expression of DNMT3b and DNMT1 coincided with upregulated NEK2 expression (Figure S7B, Supporting Information). When DNMT3b and DNMT1 were depleted via shRNA, NEK2 mRNA and protein expression levels were dramatically downregulated in H929 cells with or without p53 expression (Figure 7H,I, Figure S7C–F, Supporting Information). lower NEK2 expression levels were found in H929-Ctrl cells expressing wild type p53. Additionally, a co-immunoprecipitation assay showed that p53 interacted strongly with NEK2 in H929-Ctrl cells (Figure S7B, Supporting Information). We also confirmed that NEK2 expression levels decreased in p53-overexpressing ARP1 cells (Figure S7F, Supporting Information). These results suggested that p53 promotes its binding region in the NEK2 promoter from accumulating DNA methylation by repressing DNMT expression (Figure 7K).

2.8. TP53 Overexpression Synergistically Interacts with NEK2 Suppression to Promote Tumor Formation and Reduce Bortezomib Sensitivity

We next determined the effect of combined p53 overexpression and NEK2 suppression on chromosome stability, proliferation, and drug resistance in TP53−/− MM cell lines using in vitro and in vivo assays. Spindle formation assay experiments revealed that the number of cells with abnormal mitosis were reduced after p53 ectopic expression in ARP1 cells (ARP1-TP53 OE, 17.6 ± 0.7%) compared with control cells (ARP1-Ctrl, 19.2 ± 0.9%). Meanwhile, the number of cells with mitotic abnormalities was elevated after NEK2 overexpression in ARP1-TP53 OE cells (ARP1-TP53 OE/NEK2 OE, 21.7 ± 0.8%). However, the number of defective cells was substantially reduced when NEK2 was depleted by shRNA-mediated knockdown in ARP1-TP53 OE cells (ARP1-TP53 OE/shNEK2, 10.3 ± 0.7%) (Figure 8A). Similarly, BrdU intake assay experiments revealed that the number of BrdU-positive cells decreased significantly in the ARP1-TP53 OE group.
Figure 6. p53 deletion promotes aberrantly high NEK2 expression through indirect transcriptional regulation. A,B) Luciferase activity driven by NEK2 promoter with normal (full length) or mutant p53 binding site in HEK293-TP53KO and ARP1 cells transiently co-transfected with p53 OE. Data presented as mean ± SD, p-values are calculated using unpaired t-test, n = 3, **p < 0.01. C) ChIP confirming that the transcription factor p53 specifically binds to the NEK2 promoter region in H929 cells. Data presented as mean ± SD, p-values are calculated using unpaired t-test, n = 3, ****p < 0.0001. D) Correlation of expression between NEK2 and E2F8 in MM patients based on GEP database (GSE2658, n = 559, p-values are calculated Spearman correlation coefficient). E) The mRNA and protein levels of TP53, CDKN1A (p21), and E2F8 in H929 cells with or without p53 deletion. Here and in panels (F–J), mRNA and protein data were obtained using qPCR and immunoblotting, respectively. Data presented as mean ± SD, p-values are calculated using unpaired t-test, n = 3, ***p < 0.001. F) The mRNA and protein levels of TP53, CDKN1A (p21), and E2F8 in ARP1 cells with or without p53 overexpression. Data presented as mean ± SD, p-values are calculated using unpaired t-test, n = 3, *p < 0.05, ***p < 0.001. G,H) The mRNA and protein levels of NEK2 and E2F8 in H929-Ctrl and H929-TP53KO cells with (H929-TP53KO/E2F8 OE) or without E2F8 overexpression. Data presented as mean ± SD, p-values are calculated using unpaired t-test, n = 3, **p < 0.01. I,J) The mRNA and protein levels of NEK2 and E2F8 in ARP1-EV and ARP1-TP53OE cells with (ARP1-TP53OE/E2F8 OE) or without E2F8 overexpression. Data presented as mean ± SD, p-values are calculated using unpaired t-test, n = 3, **p < 0.01. K) ChIP confirmed that the transcription factor E2F8 specifically binds to the NEK2 promoter region. L) Schematic of p53 deletion enhancing NEK2 expression through E2F8 upregulation.
**Figure 7.** p53 suppresses NEK2 expression by regulating the expression of DNMTs. 

A) Detailed BGS analysis confirmed methylation status of the NEK2 promoter’s distal CpG island in H929 cells with or without p53 deletion. B) Statistical analysis of methylated CpG dinucleotides in the NEK2 promoter’s distal CpG nucleotides in H929 cells with or without p53 deletion. Data presented as mean ± SD, n = 11, p-values are calculated using one-way ANOVA with Bonferroni correction, **p < 0.01, ****p < 0.0001. C) Heatmap of the ratios of the signal intensities of differential methylation-related genes in H929 cells with or without p53 deletion.
but increased in the ARP1-TP53 OE/NEK2 OE group, compared with ARP1-EV cells. In contrast, the number of defective cells decreased dramatically in ARP1-TP53 OE/shNEK2 cells compared to ARP1-EV or ARP1-TP53 OE cells (Figure 8C,D).

Subsequently, we tested the sensitivity of cells with combined p53 and NEK2 depletion to BTZ by using an apoptosis assay. We found that the percentage of apoptotic cells increased significantly in the ARP1-TP53 OE/shNEK2 group (30.0 ± 3.04%) after 4 nM BTZ treatment when compared with the ARP1-Ctrl (14.1 ± 1.41%) and ARP1-TP53 OE (17.3 ± 0.42%) groups (Figure 8E,F).

In addition, by using an MM xenograft model with B-NDG immunodeficient mice, we confirmed that the tumor sizes produced from ARP1-TP53 OE cells were much smaller than those from ARP1-EV or ARP1-TP53 OE/NEK2 OE cells (Figure 8G,H). Furthermore, tumors formed by ARP1-TP53 OE/shNEK2 cells were the smallest and were much more sensitive to BTZ than were ARP1-TP53 OE cells (Figure 8G,I). Subsequent IHC analysis also revealed that cells in tumor nodules were CD138⁺ (Figure S8A, Supporting Information), and the number of Ki-67⁺ cells was reduced, suggesting that the recovery of p53 function and further suppression of NEK2 are beneficial for the p53-deleted mice.

3. Discussion

Collaboration between oncogenes and tumor suppressor genes is an important mechanism in the development of MM. Here, we showed that NEK2 amplification is a major cause for NEK2 up-regulation in MM and other cancer types, especially in TP53-deleted MM patients. Previously, we had reported that NEK2 overexpression induces drug resistance, proliferation and CIN in cancer cells. In this study, we found that patients with combined defects of NEK2 activation and p53 inactivation suffer from poor survival and that collaboration between NEK2 and TP53 defects augments MM cell growth and drug resistance in vitro and in vivo. Gene mutations, DNA amplification and promoter methylation status are the major causes for aberrantly high expression of candidate tumor genes. Previous studies focused on the function, mechanisms and protein stability of NEK2, but how NEK2 is activated and upregulated remained poorly understood. In this study, using a FISH probe for NEK2 DNA, we examined the copy number of NEK2 in MM cells and patients and assessed mutations in the NEK2 promoter and exons. We further examined DNA methylation in the proximal and distal NEK2 promoter regions in MM cell lines and analyzed the effect of NEK2 mutation on its expression (data not shown) using genomic data from a recent MMRF study (study accession phs000748). Interestingly, we found that NEK2 is only amplified in the MM cells of patients who have a poor rate of survival, suggesting that NEK2 amplification is the major cause for NEK2 activation in MM. To date, NEK2 DNA amplification in tumors is still poorly documented due to a lack of appropriate FISH probes for detecting the chromosomal copy number of NEK2. In our present study, we prepared a DNA probe of NEK2 to detect its copy number with FISH, leading us to find that NEK2 amplification occurs in 23.5% of MM (AD) patients, similar to the data from MMRF study. Thus, it is highly likely that our prepared DNA probe can be used for clinical detection of NEK2 amplification in the future.

The 17p chromosomal region harbors the gene locus of TP53, an important tumor suppressor gene. Deletion of this region is a recurrent cytogenetic abnormality present in 10–34% of MM cases along with disease progression and is considered an independent factor responsible for less favorable clinical outcome in MM patients. In keeping with this notion, the lesions associated with short OS in multivariate analysis are +1q and del17p13 in MM, suggesting that the combined cytogenetic abnormality contributes to the progression of MM. Despite these advances, the molecular mechanisms underlying p53’s action are poorly understood. MDM4, a homolog of MDM2, is located in the +1q region and inactivates p53 by binding to and inhibiting its transactivation. Whether this occurs in MM is unknown. Our current studies demonstrated that NEK2 amplification correlates strongly with TP53 deletion in MM and has a significant clinical impact. Previously, it had been reported that NEK2 and p53 modulate each other. On the one hand, methylation of the distal NEK2 promoter containing the p53-binding site affects p53 binding to the promoter, resulting in the inability of p53 to attenuate NEK2 expression. On the other hand, NEK2 can attenuate the function of wild type p53 by inhibiting its phosphorylation.

In this study, we found, that under normal physiological conditions, p53 is an active protein that binds to the transactivation domain in the NEK2 promoter. This inhibits NEK2 transcription through the cell cycle pathway mediated by p53-p21-DREAM-E2F and protects its distal CpG island from increased methylation. The E2F transcriptional factors mediate various biological functions involved in cell cycle progression. Previous studies suggested that cell cycle arrest is achieved through indirect transcriptional repression by p53-p21-DREAM-E2F/CHR. In this pathway, the target genes with E2F or CHR promoter sites are transcriptionally regulated by the DREAM transcrip-
Figure 8. Downregulation of NEK2 in TP53-deleted MM cells inhibits cell growth and decreases drug resistance. A, B) Representative images of spindles (Red, Tubulin), GFP (Green), and nuclei (Blue) in ARP1-Ctrl, ARP1-TP53 OE, and ARP1-TP53 OE/shNEK2 cells. Quantifications show the percentage of abnormal monopolarity from three independent experiments. At least 60 spindles were randomly chosen and counted in each experiment. All results are shown as means ± SD of three independent experiments. Data presented as mean ± SD, p-values are calculated using one-way ANOVA with Dunnett post-hoc test, *p < 0.05, **p < 0.01. C) Representative histograms for detection of apoptotic cells and D) statistical analysis of the percentage of apoptotic cells in ARP1-Ctrl, ARP1-TP53 OE, ARP1-TP53 OE/NEK2 OE, and ARP1-TP53 OE/shNEK2 cells treated with 4 nM BTZ for 48 h. Data presented as mean ± SD, p-values are calculated using one-way ANOVA with Dunnett post-hoc test, n = 3, *p < 0.05, **p < 0.01. E) Representative images for IHC detection of Ki-67 protein in the tumor nodules derived from B-NDG mice injected subcutaneously with ARP1-Ctrl, ARP1-TP53 OE, ARP1-TP53 OE/NEK2 OE, or ARP1-TP53 OE/shNEK2 cells (n = 4). Cells were treated I) with BTZ or H) with PBS as a negative control. Tumor volumes of xenografts derived from B-NDG mice injected with ARP1-Ctrl, ARP1-TP53 OE, ARP1-TP53 OE/NEK2 OE, or ARP1-TP53 OE/shNEK2 cells into the right abdomen. Cells were treated with BTZ or with PBS as a negative control. Data presented as mean ± SD, p-values are calculated using two-way ANOVA with Dunnett post-hoc test, n = 6, *p < 0.05, **p < 0.01, ***p < 0.001. J) Representative images for IHC detection of Ki-67 protein in the tumor nodules derived from B-NDG mice injected subcutaneously with ARP1-Ctrl, ARP1-TP53 OE, ARP1-TP53 OE/NEK2 OE, or ARP1-TP53 OE/shNEK2 cells. Cells were treated with BTZ (right) or with control (left).
In conclusion, we found that p53 inhibits NEK2 transcription, while mutant p53 significantly increases its expression. Finally, at the functional level, combined TP53 deletion and NEK2 overexpression in WT TP53 MM cell lines induces asymmetric mitosis and promotes proliferation and tumorigenic activity in vitro and in vivo. Conversely, concomitant p53 overexpression and NEK2 inhibition in TP53−/− cells can partially rescue these defects, including drug resistance, in MM cells in vitro and in vivo.

A preclinical study using myeloma demonstrated that adenovirus-mediated delivery of WT TP53 can potentially induce apoptosis. Our current study also suggests that delivery of WT TP53 and inhibition of NEK2 in a TP53−/− MM cell line can suppress tumor formation and enhance BTZ’s therapeutic effect. Our findings suggest that targeting the function of the NEK2 and p53 pathways may have therapeutic values by reversing the adverse outcome of MM patients without p53.

In conclusion, we found that NEK2 amplification leads to NEK2 upregulation, while combined defects in TP53 and NEK2 can be used as a novel marker for poor prognosis in a cohort of MM patients. We also validated NEK2 as a novel therapeutic target in the TP53−/− subset of MM and revealed a novel mechanism by which TP53 regulates NEK2 at both the genetic and transcriptional levels. Future experimentation should examine the clonal evolution of the subgroup containing TP53 and NEK2 dual defects and their functions in MM initiation, promotion and drug resistance. Selective inhibitors should be developed to improve the clinical outcomes for these patients.
4. Experimental Section

Human Samples: Human bone marrow samples were obtained from healthy donors (n = 8) and newly diagnosed (n = 82) and relapsed (n = 25) MM patients in the Third Xiangya Hospital, Central South University (Changsha, China) and Institute of Hematology and Blood Disease Hospital, Chinese Academy of Medical Sciences and Peking Union Medical College (Tianjin, China). Written informed consent was obtained from all participants. The sampling procedure was approved by the Cancer Research Institute of the Central South University Medical Ethics Committee. Primary MM cells and normal plasma cells were isolated from the mononuclear cells of BM samples using CD138 MicroBeads (Miltenyi Biotec, Auburn, CA).

Cell Culture and Reagents: The human MM cell lines H929, MM.1S, MM.1R, RPMI-8226, and U266 were purchased from the American Type Culture Collection (ATCC, Manassas, VA). HEK293, ARP1, and OCI-my5 cell lines were obtained from the Cancer Research Institute of Central South University. HCT116-TP53WT and HCT116-TP53 cells were kindly provided by Dr. Tiebang Kang (Sun Yat-sen University Cancer Center, Guangzhou, China). Non-human primates were sacrificed in strict accordance with the regulations of the Chinese Academy of Medical Sciences. We used the accessory primate cells (HEK293, ARP1, and OCI-my5) derived from the non-human primate MA, USA.

Vectors and Transfections: NEK2, E2F8, and wild type and mutant TP53 cDNAs containing open reading frames (ORF) were subcloned into the pcDNA vector tagged with GFP or RFP (#CDS118-1, Addgene, Watertown, MA, USA). NEK2, E2F8, and wild type TP53 ORF sequences (Table S10, Supporting Information) were amplified by RT-PCR using RNA purified from HEK293 cells as a template with TP53-ORF primers and confirmed by sequencing. Mutant TP53 expression vector was obtained from wild type TP53 expression vector by site-directed mutagenesis (Supporting Information 3). The shRNAs (shRNA sequence for NEK2 and E2F8 is shown in Table S10, Supporting Information) were inserted into EcoRI and Xhol sites of the pLKO vector tagged with Tet and puromycin (Addgene). Lentiviruses expressing shRNAs against NEK2 and E2F8 were used to infect MM cells. The infected cells were sorted by flow cytometry by GFP or RFP 5 days post-infection. Single colonies were obtained by sequential dilution after infection. Single colonies were picked and expanded to derive isogenic cell lines with defined mutations. To obtain H929 cell lines with TP53 gene knockout, pL-CRISPR.EFS.GFP-TP53 plasmids and sorted by GFP 5 days after infection. Single colonies were obtained by sequential dilution after sorting (Supporting Information 3). Deletion of the TP53 gene in selected HEK293 and H929 cell clones was confirmed by qPCR and western blotting. The shRNA guide sequences and genotyping primers are listed in Table S10, Supporting Information.

Fluorescence In-Situ Hybridization: FISH was performed on interphase nuclei using established methods.[11] As previously described, all MM cell samples were purified using Miltenyi technology (anti-CD138-coated magnetic beads) before FISH. To detect NEK2 amplification, a CEPI probe targeting chromosome 1 (#CHR01-10-G, Empire Genomics, Buffalo, NY, USA) and a bacterial artificial chromosome (BAC) at 1q22.2 (#RP11-114G13, Invitrogen) were purchased. The BAC probe was labeled using the Nick Translation Kit (#32-801300, Abbott, Chicago, USA) with green-dUTP (#02N32-050, Abbott) or orange PF55-dUTP (#PK-PF55-S-100, PromiKone, Germany). The status of the TP53 gene was analyzed using a DNA probe targeting TP53 (#TP53-20-OR, Empire Genomics). Interphase FISH was performed according to the procedure described previously. Briefly, the probes were hybridized to CD138+ cells. The slides were stored at 4 °C until FISH analyses were performed. Interphase FISH signals were evaluated in at least 200 interphase nuclei in each sample. If at least three copies were seen in at least 20% of CD138+ cells, it was considered evidence of gain/amplification. To investigate effects of the magnitude of copy number alteration (CNA), the NEK2 locus was divided into two categories: 1) Three copies of the NEK2 probe (the percentage of clonal plasma cells with at least three copies was <20%) and 2) more than three copies of NEK2 probe (the percentage of clonal plasma cells with more than three copies was ≥20%).

Soft Agar Clonogenicity Assay: 1000 cells per well were seeded in 12-well plates for double-layer agar cultures for 3 weeks. Cells were resuspended in 0.3% agar (#16 520 100, Invitrogen) in RPMI-1640 medium supplemented with 15% FBS. Cells were incubated (37 °C, 5% CO2) and fed with the same medium every three days on the up-layer for three weeks. The aggregates of cells >50 cells were defined as colonies. Photographs of all plates were scanned with ChemiDoc XRS (Bio-Rad, California, USA), and the colonies were counted using ImageJ (NIH, USA).

BrdU Assay: For the BrdU assay, all procedures followed the standard protocol with the APC BrdU Flow Kit (#552598, BD, New Jersey, USA). Cells were labeled with BrdU in culture medium for 1 h. Subsequently, the incorporated BrdU was stained with specific anti-BrdU fluorescent antibodies, and 7-aminoactinomycin D (7-AAD) was used to label total DNA in conjunction with BrdU staining. Finally, cells stained with BrdU and 7-AAD were acquired by flow cytometry and analyzed with FlowJo software.

Apoptosis: Apoptotic cells were labeled by APC-conjugated Annexin V (BD). Dead cells were labeled by 7-AAD (BD). Cell staining was performed according to the manufacturer’s protocol. Labeled cells were then measured by CytoFLEX (Beckman Instruments, Inc, CA, USA). The percentages of apoptotic cells were calculated using FlowJo software.

Immunofluorescence: Bone marrow aspirates from human myeloma patients were sorted with anti-CD138 magnetic beads and mounted onto cytosin slides for this study. Myeloma cells were fixed in 4% formaldehyde, and primary antibodies against NEK2 (mouse anti-human, #D-8, sc-1514G13, Invitrogen) and a bacterial artificial chromosome (BAC) at 1q32.2 (#RP11-114G13, Invitrogen) were added at a final dilution of 1:100 followed by overnight incubation at 4 °C. The secondary antibodies goat anti-rabbit Alexa Fluor 488 (#A21202, Invitrogen) and goat anti-mouse Alexa Fluor 594 (#A21207, Invitrogen) were added at a final dilution of 1:1000 for 1 h at room temperature. The slides were washed and mounted with DAPI. Images were captured using a confocal microscope (Nikon, Tokyo, Japan).

Luciferase Activity Assay: The NEK2 promoter sequence ranging from −1017bp to −2bp, with or without the p53 binding site, was inserted into a pGL3-enhancer vector (Promega, Wisconsin, USA) and subsequently a luciferase reporter gene vector. The luciferase reporter gene constructs were named pGL3-NEK2-P6 and pGL3-NEK2-P6M, respectively. Subsequently, pGL3-control (positive control, Promega), pGL3-NEK2-P6, and pGL3-NEK2-
P6M, and the internal control Renilla (pRL-null, #E2271, Promega) vectors were co-transfected with wild type pcDNA3.1-TP53-FLAG and the TP53 expression vector into HEK293-TP53KO and AR1P cells using Lipofectamine 3000. Cells were harvested after 48 h cultivation, and a luciferase activity was detected using Dual-Luciferase Reporter Assay System (Promega) and a GloMax 20/20 Luminometer (Promega) according to the manufacturer’s protocol. All samples were done in triplicate. The primers for luciferase reporter gene constructs are listed in Table S10, Supporting Information.

**Chromatin Immunoprecipitation:** The binding of the NEK2 subunit to DNA in TP53-knockout H929-T53KO and wild type TP53 H929-Ctrl MM cell lines was quantified with ChIP-quantitative PCR (ChIP-qPCR). The chromatin immunoprecipitation (ChIP) assay was performed with the EZ-ChIP kit (#17-371 RF, Millipore, Massachusetts, USA). Briefly, chromatin (5 μg) from the two myeloma cell lines was used in the ChIP assay using antibodies (3 μg) against p53 (DO-1, #sc-126 X, Santa Cruz Biotechnology) or E2F8 (#13425-1-AP, Proteintech). The ChIP DNA fragments were quantified with the EZ-ChIP kit and the enrichment of DNA fragments containing putative p53 binding sites in the gene promoter was quantified by qPCR using a LightCycler 96 (Roche, Basel, Switzerland). Two specific primers for NEK2, p21, and GAPDH (Table S10, Supporting Information) were used to amplify fragments containing the predicted p53 or E2F8 binding sites in the NEK2 promoter region. As a negative control, GAPDH was also amplified with the corresponding primers, while p21 was used as a positive control. Values obtained from immunoprecipitated samples were normalized to that of their corresponding input samples. Data are representative of three separate experiments, and error bars indicate mean ± SD. The primers used in the ChIP-qPCR assay are listed in Table S10, Supporting Information.

**Comparative Genomic Hybridization:** A CGH array of HEK293-TP53KO and HEK293-NEK2 OE versus HEK293-Ctrl cells was performed to identify, in combination with bioinformatics, amplified or deleted genes among these three cell types. The SurePrint G3 Human CGH Microarray Kit, 2 × 400K chip (Agilent, California, USA) to detect genome-wide differences was used. After the completion of hybridization, the array slides were taken out and washed, then placed into an Agilent Microarray Scanner for scanning. After scanning, the data were interpreted with Agilent Feature Extraction software. The CGH differential region was then calculated using Agilent CytoGenomics software. The detection method is numbered AG-GC-WL01-01-2012, and the data analysis method is numbered AG-GC-DL01-01-2010. The whole testing process was completed by Capital Bio Technology (Shanghai, China).

**Assessment of Mitotic Spindle Phenotypes:** Assessment of mitotic spindle phenotypes was performed according to the procedure described previously.[9] Briefly, cells were fixed in 4% paraformaldehyde (PFA, 110, Solarbio, Beijing, China), permeabilized by 0.1% Triton X-100 (Sigma-Aldrich) and incubated with fluorescent anti-α-tubulin (#ab7291, Abcam, Cambridge, UK) at 1:1000 dilution for 2 h, with the secondary antibodies goat anti-mouse Alexa Fluor 594 (#A21207, Invitrogen) at 1:1000 dilution for 1 h and 0.1 μg mL⁻¹ DAPI (#D9564-10MG, Sigma-Aldrich) for 5 min at room temperature. Cells were then analyzed by Axio Imager Z2 (Carl Zeiss, Oberkochen, Germany) and images were recorded using DeltaVision OMX 3D (Applied Imaging, Santa Clara, USA). AXIO Imager, Z2 Metafer fluorescence microscopy (Zeiss, Oberkochen, Germany), and the analysis of the images were performed by ImageJ (National Institutes of Health). Slides were allowed to air dry and placed in a 37 °C oven for 30 min. The tissue sections were incubated with the primary antibodies anti-CD138 (#10593-1-AP, Proteintech), anti-NEK2 (D-8, #sc-55601, Santa Cruz Biotechnology), p53 (#AMO183, Spectre, Xiamen, China), and Ki-67 (#AMO383, Spectre) at a final dilution of 1:100 overnight at 4 °C. As a negative control, the stained proteins was washed out by incubating both the PBS and NBT (Invitrogen). The slides were then washed with TBS-T, followed by incubating with species-specific secondary HRP-conjugated antibodies conjugated, which were diluted in secondary HRP-conjugated antibodies (3 μg mL⁻¹) (Whole Rabbit Anti-Human IgG H&L (HRP) #SP9002, Vector Laboratories, Peterborough, UK) at 1:1000 dilution for 1 h and 0.1 μg mL⁻¹ DAPI (#D9564-10MG, Sigma-Aldrich) for 5 min at room temperature. The tissue sections were analyzed with a confocal microscope and the analysis of images was performed by ImageJ (National Institutes of Health). The analysis was completed by the laboratory of Dr. W. T. Ju (Beijing Normal University, Beijing, China).

**Immunohistochemistry Staining:** Tumor xenografts derived from mice in vivo were fixed in formalin for 48 h. Then, microarray slides were cut at four microns on plus slides. IHC was performed using a standard streptavidin-biotin-peroxidase complex method as previously described.[9] Slides were allowed to air dry and placed in a 55–60 °C oven for 30 min. The tissue sections were incubated with the primary antibodies anti-CD138 (#10593-1-AP, Proteintech), anti-NEK2 (D-8, #sc-55601, Santa Cruz Biotechnology), p53 (#AMO183, Spectre, Xiamen, China), and Ki-67 (#AMO383, Spectre) at a final dilution of 1:100 overnight at 4 °C. The intensity of the stained proteins was determined by measuring both the intensity (0, 1, 2, and 3) and extent of staining (0%, < 10%; 2–10%; 30–50% and >30%) as previously described.[9] The images were then analyzed by ImagePro Plus software (Media Cybernetics, Silver Spring, MD). Immunohistochemistry-stained slides were imaged using a fluorescence microscope (Eclipse 80i, Nikon, Tokyo, Japan). The images were analyzed with ImageJ (National Institutes of Health).

**Real-Time Quantitative PCR:** For quantitative analysis of gene expression, total RNA was isolated with Trizol. Complementary DNA was synthesized using a full cDNA transcription kit according to the manufacturer’s instructions (#KT1622, Thermo Fisher). Real-time qPCR for human NEK2, TP53, E2F8, GAPDH, and other genes listed below was performed using SYBR Green Super Mixture Reagents (#A25742, Invitrogen) on a LightCycler 96 system (Roche). PCR was initiated at 95 °C for 2 min to hot-start the DNA polymerase and denature the template, followed by 40 cycles of denaturing at 95 °C for 15 s and annealing and extension at 60 °C for 1 min. The primers used in the qPCR assay are listed in Table S10, Supporting Information.

**Immunoblotting:** Cell pellets were lysed with RIPA lysis buffer and 20–40 μg protein from each experimental condition were subjected to sodium dodecyl sulfate-polyacrylamide gel electrophoresis, which was then transferred onto a polyvinylidene fluoride membrane. The membranes were blocked with 5% nonfat dry milk in Tris-buffere d saline solution containing 0.1% Tween 20 (TBS-T) for 1 h at room temperature and then incubated with the appropriate primary antibodies overnight at 4 °C. The membranes were washed with TBS-T, followed by probing with species-specific secondary HRP-conjugated antibodies conjugated, which were diluted in 1:1000 dilution for 1 h and 0.1 μg mL⁻¹ DAPI (#D9564-10MG, Sigma-Aldrich) for 5 min at room temperature.

All sequencing reads were aligned with the reference genome (GRCh38) using HISAT2[23] with default options in the StringTie[20] RNA-seq workflow.[21] After the removal of improperly aligned reads, read count information was extracted from the files generated by StringTie with a provided Python script (prepDE.py). Finally, EdgeR[22] in R was used to screen differentially expressed genes in the samples.
bovine serum albumin with TBS-T. Protein bands were detected using SuperSignal West Pico Chemiluminescent Substrate (Pierce, Rockford, IL, USA).

Methylation-Specific PCR: MSP was performed using our previously published protocol.[35] Briefly, MSP was carried out for 45 cycles using the Ex Taq Hot Start DNA polymerase (#RR006A, Takara, Dalian, China) with 10 ng of sodium bisulfite-treated DNA. MSP products (both U and M products) of NEK2 from partial samples, which accounted for 20% of all detected samples, were purified with Agarose Gel Purified System (#LS1022, QIAGEN, Promega) and subsequently sequenced. All sequencing reactions were performed by a 377 ABI PRISM DNA Sequencer at the Shanghai Invitrogen Company (Shanghai, China). The primers used in the MSP assay are listed in Table S10, Supporting Information.

For Bisulfite Genomic Sequencing, primers were designed with MethPrimer 2.0 tools online (Table S10, Supporting Information). After PCR amplification was performed from deaminated DNA, products were gel-purified and connected to T vector. Ten clones were randomly selected for sequencing and analysis by the use of NCBI Nucleotide BLAST.

Co-Immunoprecipitation: For co-IP analysis, the H929-Ctrl and H929-TP53KO cell lines were used. All procedures followed the standard protocol previously reported.[11,14] Briefly, cells were lysed in lysis buffer for 40 min on ice. The lysates were incubated overnight at 4 °C on a rotator with 4 μg of polyclonal anti-p53 and mouse IgG antibodies (Santa Cruz Biotechnology, CA, USA). 50 μL of protein A/G beads (Biolinkedin, Shanghai, China) were transferred to the protein-antibody complexes, and immunoprecipitates were collected after 2 h incubation. Finally, the immunoprecipitates were resuspended in lithium dodecyl sulfate (LDS) sample buffer and heated for 10–12 min at 70 °C for analysis by LDS polyacrylamide gel-electrophoresis, loading equal concentrations of protein from the original lysate, and western blotting with monoclonal antibodies against p53 (ABClonal, Shanghai, China), DNMT1, and DNMT3B (Proteintech).

Statistical Analysis: Quantitative data are shown as means ± SD. Student’s t-test, ANOVA with Dunnett post-hoc test, Chi-square and Rank sum tests were used to analyze data. To analyze correlation of tests were used to analyze data. To analyze correlation of data, the log-rank test was used for group comparison based on GraphPad Prism 7 software. Significance was set at $p < 0.05$.

Supporting Information
Supporting Information is available from the Wiley Online Library or from the author.

Acknowledgements
X.F. and J.G. contributed equally to this work. The authors would like to thank Prof. Jun Zhou and Prof. Dengwen Li of the Key Laboratory of Medicinal Chemical Biology, College of Life Sciences, Nankai University (Tianjin, China) for technical assistance in the assessment of mitotic spindle phenotypes. The authors would also like to thank Prof. Tiebang Kang of Sun Yat-sen University Cancer Center (Guangzhou, China) for providing CRISPR-Cas9-Lenti-TP53. The authors extend a special thanks to all patients, their caregivers, and referring physicians for making this work possible. This work was supported by the Ministry of Science and Technology of China (2018YFA0107800), National Natural Science Foundation of China (82130006, 81974010, 81630007), National Natural Science Foundation of Hunan Province (2020WK2006, 2021J13089), Strategic Priority Research Program of Central South University (ZLDX2017004), SKLEH-Pilot Research Grant (ZK16-04, ZK21-05), and Fundamental Research Fund for Graduate of Central South University (2019zztsB07). The authors thank Dr. Daniel Ackerman of Insight Editing London for editing the manuscript during submission.

Conflict of Interest
The authors declare no conflict of interest.

Author Contributions
X.F. and J.G. contributed equally to this work. W.Z., X.F., and J.G. conceived of and designed the experiments; X.F., J.G., Y.W., B.M., Y.Z., L.Q., R.L., and J.X. performed the experiments; W.Z., X.F., J.G., Z.Y., and Z.L. analyzed the data; X.L., G.A., C.R., L.Q., and J.Z. provided critical materials; W.Z., X.F., and J.G. wrote the manuscript and all authors edited the manuscript.

Data Availability Statements
The data that support the findings of this study are available in the supplementary material of this article.

Keywords
amplification, multiple myeloma, NEK2, TP53, transcriptional regulation
